Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05773326 | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | terminated | Early Phase 1 | 5 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07042620 | A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery | active not recruiting | N/A | 15 | SonoClear ASINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07585851 |
| Administration of Repurposed Ketoconazole in Glioma Patients |
| active not recruiting |
| Early Phase 1 |
| 80 |
| Universitas PadjadjaranOTHER |
| 1 |
| May 14, 2026 |
| clinicaltrials |
| NCT06528691 | Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors | recruiting | Phase 2 | 52 | St. Jude Children's Research HospitalOTHER | 4 | May 13, 2026 | clinicaltrials |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04975139 | Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks | active not recruiting | — | 71 | Washington University School of MedicineOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03382977 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | terminated | Phase 1 / Phase 2 | 70 | VBI Vaccines Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06136611 | Preoperative Preradiotherapy TTFields(PORTRAIT) | recruiting | N/A | 42 | The Christie NHS Foundation TrustOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06964737 | Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas | recruiting | Phase 1 | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04015700 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT06796335 | Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour | completed | — | 35 | Rigshospitalet, DenmarkOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07284069 | Senicapoc and Perampanel for Newly Diagnosed Glioblastoma(SENIPERA) | recruiting | Early Phase 1 | 36 | Aarhus University HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme(PAZOGLIO) | active not recruiting | Phase 1 / Phase 2 | 51 | Centre Antoine LacassagneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04699773 | LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) | recruiting | N/A | 32 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05293197 | Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients(SONOKID) | recruiting | Phase 1 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | terminated | Phase 1 | 7 | Nicholas ButowskiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06636162 | Window of Opportunity Study of DSP-0390 in Gliomas | recruiting | Early Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07343986 | Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma(BATs FUS) | recruiting | Phase 1 | 12 | University of VirginiaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04274283 | Tessa Jowell BRAIN MATRIX - Platform Study(BRAIN MATRIX) | recruiting | — | 1,000 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05091866 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | terminated | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05629702 | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids(ARISTOCRAT) | recruiting | Phase 2 | 120 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06649851 | G-CSF After Chemo-radiation in Patients With Glioblastoma | recruiting | Phase 2 | 60 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07567196 | PET-Guided Resection in High-Grade Gliomas(ResPGlioma) | recruiting | — | 100 | Universita degli Studi di GenovaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07567469 | A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 0 | May 5, 2026 | clinicaltrials |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | active not recruiting | Phase 1 / Phase 2 | 52 | Inovio PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05241392 | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | active not recruiting | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05743595 | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06176066 | PH Sensitive MRI Based Resections of Glioblastoma | recruiting | Phase 1 | 18 | University of California, Los AngelesOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05190172 | PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas(PRO-GLIO) | recruiting | N/A | 225 | Oslo University HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | recruiting | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562971 | Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)(FIDES) | not yet recruiting | Phase 1 / Phase 2 | 20 | UMC UtrechtOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01096368 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | completed | Phase 3 | 479 | Children's Oncology GroupNETWORK | 4 | Apr 30, 2026 | clinicaltrials |
| NCT05283109 | ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM(ETAPA I) | active not recruiting | Phase 1 | 24 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07365124 | MRinRT: Swansea University and SWWCC Collaboration Study.(MRinRT) | not yet recruiting | — | 165 | Swansea Bay University Health BoardOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07443176 | FCI-Glioblastoma Study | not yet recruiting | — | 18 | University of AberdeenOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04540107 | Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma | recruiting | Phase 1 | 300 | Susan ChangOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06625047 | Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy | completed | Phase 4 | 30 | Mayo ClinicOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07297212 | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma | recruiting | Phase 2 | 75 | BioNTech SEINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04922723 | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma(PRIDE) | active not recruiting | Phase 1 / Phase 2 | 16 | West Virginia UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06039709 | Sonodynamic Therapy in Patients With Recurrent GBM(GBM 001) | recruiting | Phase 1 | 11 | Shayan Moosa, MDOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07553520 | Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients | withdrawn | N/A | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552233 | NK Cell Therapy for Malignant Solid Brain Tumors | recruiting | N/A | 27 | Peking University Third HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors | recruiting | — | 26 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03363217 | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | active not recruiting | Phase 2 | 114 | St. Justine's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05513859 | Investigational Imaging Technique During Brain Surgery | suspended | N/A | 24 | Emory UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05565521 | UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly(UNITED2) | active not recruiting | Phase 2 | 55 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 14, 2026source: clinicaltrials